Mutations in IDH1 (~80% of grade II-III gliomas and secondary GBMs and ~5% of primary GBMs) and less frequently IDH2 are characteristic of secondary GBM and are associated with a better prognosis [28,33]. The gene discussed is IDH2; the disease is central nervous system cancer.